Multicenter Italian Cohort Study on Tuberculosis in Pediatric Age
Conditions: Tuberculosis Infection Sponsors: Meyer Children ' s Hospital IRCCS Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 4, 2024 Category: Research Source Type: clinical trials
Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB Prevention
Conditions: Pediatric HIV Infection; Latent Tuberculosis Interventions: Drug: Rifapentine; Drug: Dolutegravir Sponsors: Brigham and Women ' s Hospital; APIN Public Health Initiatives; University of Cape Town Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials
Diagnosis Test of Real-time Polymerase Chain Reaction (RT-PCR) for Pulmonary Tuberculosis
Conditions: Tuberculosis; Pulmonary Sponsors: Khon Kaen Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials
A Study to Evaluate the Efficacy, Safety and Immunogenicity of MTBVAC in IGRA Positive Adolescents and Adults Living in a TB Endemic Region.
Conditions: Tuberculosis (TB) Interventions: Biological: MTBVAC; Biological: Placebo Sponsors: International AIDS Vaccine Initiative; Biofabri, SLU; Universidad de Zaragoza Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 22, 2024 Category: Research Source Type: clinical trials
Mycobacteriophage Treatment of Non-tuberculosis Mycobacteria
Conditions: Cystic Fibrosis; Nontuberculous Mycobacterial Lung Disease; Nontuberculous Mycobacterium Infection; Mycobacterium Infections; Mycobacterium; Pulmonary Interventions: Biological: mycobacteriophage Sponsors: National Jewish Health; Cystic Fibrosis Foundation Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 16, 2024 Category: Research Source Type: clinical trials
Shortened Regimen for Drug-susceptible TB in Children
Conditions: Tuberculosis; Tuberculosis, Pulmonary; Tuberculosis, Lymph Node; Mycobacterium Tuberculosis Interventions: Drug: Isoniazid; Drug: Rifampin; Drug: Pyrazinamide; Drug: Ethambutol; Drug: Rifapentine; Drug: Moxifloxacin Sponsors: Johns Hopkins University; United States Agency for International Development (USAID) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 12, 2024 Category: Research Source Type: clinical trials
BCG Revaccination Study in Diabetic and Non-Diabetic Adults
Conditions: Tuberculosis Interventions: Biological: BCG Danish Sponsors: University of Oxford Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 7, 2024 Category: Research Source Type: clinical trials
Korean Registry of Non-Small Cell Lung Cancer Patients With EGFR Mutation
Conditions: NSCLC Sponsors: Yuhan Corporation; The Korean Academy of Tuberculosis and Respiratory Diseases Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 7, 2024 Category: Research Source Type: clinical trials
Evaluation of Xpert MTB/RIF Ultra in Stools and Urine to Improve Tuberculosis Diagnosis in Children
Conditions: Tuberculosis; Pediatric Infectious Disease Interventions: Diagnostic Test: Xpert MTB/RIF Ultra in stools and urine Sponsors: Medecins Sans Frontieres, Spain; Ministry of Health, Guinea-Bissau; Ministry of Health, South Sudan; Institute of Tropical Medicine, University of Tuebingen Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 2, 2024 Category: Research Source Type: clinical trials
Phase I Clinical Trial to Evaluate the Safety of Recombinant Mycobacterium Tuberculosis Fusion Protein (EEC) in Healthy Adults Aged 18-65 and Patients With Pulmonary Tuberculosis
Conditions: Tuberculosis Interventions: Biological: Recombinant Mycobacterium Tuberculosis Fusion Protein (EEC) Sponsors: Chengdu CoenBiotech Co., Ltd; Beijing Chest Hospital, Capital Medical University; Beijing Friendship Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 25, 2024 Category: Research Source Type: clinical trials
Clinical Study of JDB0131 Benzenesulfonate Tablets in Patients With Drug-sensitive Pulmonary Tuberculosis
Conditions: Drug-resistant Tuberculosis Interventions: Drug: JDB0131; Drug: Delamanid; Drug: Ethylpyrazine rifampicide (II) Sponsors: Beijing Chest Hospital; West China Hospital; Wuhan Pulmonary Hospital (Wuhan Institute For Tuberculosis Control) Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 25, 2024 Category: Research Source Type: clinical trials
Testing Health Workers At Risk to Advance Our Understanding of TB Infection
Conditions: Tuberculosis; Tuberculosis Infection Interventions: Diagnostic Test: TB infection testing Sponsors: Beth Israel Deaconess Medical Center; University of Stellenbosch Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 24, 2024 Category: Research Source Type: clinical trials
Evaluating the Accuracy of New Tests for TB Infection Diagnosis
Conditions: Latent Tuberculosis; TB Infection; Tuberculosis Interventions: Diagnostic Test: Cy-TB test; Diagnostic Test: STANDARD F TB-Feron FIA test Sponsors: Freundeskreis F ür Internationale Tuberkulosehilfe e.V Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 24, 2024 Category: Research Source Type: clinical trials
ThiPhiSA: New Pathways to Prevention From Community TB Screening in South Africa
Conditions: Tuberculosis Interventions: Drug: TB preventive therapy (TPT) Sponsors: University of Washington; Human Sciences Research Council; National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 22, 2024 Category: Research Source Type: clinical trials
Quabodepistat in combination with delamanid and bedaquiline in participants with drug-susceptible pulmonary tuberculosis: protocol for a multicenter, phase 2b/c, open-label, randomized, dose-finding trial to evaluate safety and efficacy
The objective of this study is to evaluate the safety, efficacy, and appropriate dosing of a 4-month regimen of QBS in combination with delamanid and bedaquiline in participants with drug-susceptible pulmonary TB in comparison with the 6-month standard treatment (i.e., rifampicin, isoniazid, ethambutol, and pyrazinamide).MethodsThis phase 2b/c, open-label, randomized, parallel group, dose-finding trial will enroll approximately 120 participants (including no more than 15% with human immunodeficiency virus [HIV] coinfection) aged ≥ 18 to ≤ 65 years at screening with newly diagnosed pulmonary drug-sensitive TB from ~8 si...
Source: Trials - January 19, 2024 Category: Research Source Type: clinical trials
